LDL Cholesterol

LDL-C is the amount of cholesterol carried inside low-density lipoprotein particles. It is the most familiar lipid number and the traditional primary target of cholesterol-lowering therapy.

LDL particles deposit cholesterol in the artery wall, and decades of evidence show that lowering LDL-C reduces heart attacks and strokes in proportion to how much, and how long, it is lowered. LDL is causal, not merely associated.

1. 1

   FoundationCardiovascular HealthThe best place to understand what actually prevents heart disease.
2. 2

   ConditionAtherosclerotic Cardiovascular DiseaseThe disease behind most heart attacks and strokes
3. 3

   Signal RecordOmega-3 Fatty AcidsFish Oil / EPA + DHA
4. 4

   Body SystemCardiovascularHeart function, blood pressure, and circulatory health.
5. 5

   BiomarkerApolipoprotein BThe atherogenic particle-count marker

1. Measure it
2. Understand your result
3. See what raises and lowers it
4. Apply evidence-based interventions
5. Recheck on your review cadence

An orientation to how this topic is typically approached — not medical advice.

Higher LDL-C means more cholesterol delivered to the artery wall over time. In insulin resistance or high triglycerides, LDL-C can understate risk — ApoB or non-HDL cholesterol then give a fuller picture.

• Lipid panel (calculated or direct)
• Historically required fasting; direct assays do not

That lowering LDL reduces cardiovascular events is one of the most thoroughly proven relationships in medicine, established by randomized trials and human genetics across many drug classes.

• 2018 ACC/AHA Cholesterol Guideline
• 2019 ESC/EAS Dyslipidaemia Guidelines
• Cholesterol Treatment Trialists' Collaboration meta-analyses

Sources are named authoritative guidelines and scientific bodies. Biomarker pages present established clinical context; calibrated evidence verdicts on specific interventions live in the linked Signal Records.